These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 33329575)

  • 1. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
    Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
    Front Immunol; 2020; 11():590072. PubMed ID: 33329575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
    Maharaj K; Powers JJ; Achille A; Deng S; Fonseca R; Pabon-Saldana M; Quayle SN; Jones SS; Villagra A; Sotomayor EM; Sahakian E; Pinilla-Ibarz J
    Blood Adv; 2018 Nov; 2(21):3012-3024. PubMed ID: 30425065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
    Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
    Laino AS; Betts BC; Veerapathran A; Dolgalev I; Sarnaik A; Quayle SN; Jones SS; Weber JS; Woods DM
    J Immunother Cancer; 2019 Feb; 7(1):33. PubMed ID: 30728070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma.
    Peng X; Li L; Chen J; Ren Y; Liu J; Yu Z; Cao H; Chen J
    J Med Chem; 2022 Feb; 65(3):2434-2457. PubMed ID: 35043615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
    McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
    Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
    Ioannou N; Hagner PR; Stokes M; Gandhi AK; Apollonio B; Fanous M; Papazoglou D; Sutton LA; Rosenquist R; Amini RM; Chiu H; Lopez-Girona A; Janardhanan P; Awan FT; Jones J; Kay NE; Shanafelt TD; Tallman MS; Stamatopoulos K; Patten PEM; Vardi A; Ramsay AG
    Blood; 2021 Jan; 137(2):216-231. PubMed ID: 33024998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
    Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
    Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Bobrowicz M; Dwojak M; Pyrzynska B; Stachura J; Muchowicz A; Berthel E; Dalla-Venezia N; Kozikowski M; Siernicka M; Miazek N; Zapala P; Domagala A; Bojarczuk K; Malenda A; Barankiewicz J; Graczyk-Jarzynka A; Zagozdzon A; Gabrysiak M; Diaz JJ; Karp M; Lech-Maranda E; Firczuk M; Giannopoulos K; Efremov DG; Laurenti L; Baatout D; Frenzel L; Malinowska A; Slabicki M; Zenz T; Zerrouqi A; Golab J; Winiarska M
    Blood; 2017 Oct; 130(14):1628-1638. PubMed ID: 28830887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
    Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
    Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
    Ren J; Catalina MD; Eden K; Liao X; Read KA; Luo X; McMillan RP; Hulver MW; Jarpe M; Bachali P; Grammer AC; Lipsky PE; Reilly CM
    Front Immunol; 2019; 10():2512. PubMed ID: 31708928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
    McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
    Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia.
    Smith AL; Skupa SA; Eiken AP; Reznicek TE; Schmitz E; Williams N; Moore DY; D'Angelo CR; Kallam A; Lunning MA; Bociek RG; Vose JM; Mohamed E; Mahr AR; Denton PW; Powell B; Bollag G; Rowley MJ; El-Gamal D
    JCI Insight; 2024 May; 9(10):. PubMed ID: 38775157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
    Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
    Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
    Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
    Tsuji G; Okiyama N; Villarroel VA; Katz SI
    J Allergy Clin Immunol; 2015 May; 135(5):1228-39. PubMed ID: 25458911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
    Knox T; Sahakian E; Banik D; Hadley M; Palmer E; Noonepalle S; Kim J; Powers J; Gracia-Hernandez M; Oliveira V; Cheng F; Chen J; Barinka C; Pinilla-Ibarz J; Lee NH; Kozikowski A; Villagra A
    Sci Rep; 2019 Apr; 9(1):6136. PubMed ID: 30992475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.